Cargando…

A Perspective and Framework for Developing Sample Type Specific Databases for LC/MS-Based Clinical Metabolomics

Metabolomics has the potential to greatly impact biomedical research in areas such as biomarker discovery and understanding molecular mechanisms of disease. However, compound identification (ID) remains a major challenge in liquid chromatography mass spectrometry-based metabolomics. This is partly d...

Descripción completa

Detalles Bibliográficos
Autores principales: Reisdorph, Nichole A., Walmsley, Scott, Reisdorph, Rick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023092/
https://www.ncbi.nlm.nih.gov/pubmed/31877765
http://dx.doi.org/10.3390/metabo10010008
_version_ 1783498169274859520
author Reisdorph, Nichole A.
Walmsley, Scott
Reisdorph, Rick
author_facet Reisdorph, Nichole A.
Walmsley, Scott
Reisdorph, Rick
author_sort Reisdorph, Nichole A.
collection PubMed
description Metabolomics has the potential to greatly impact biomedical research in areas such as biomarker discovery and understanding molecular mechanisms of disease. However, compound identification (ID) remains a major challenge in liquid chromatography mass spectrometry-based metabolomics. This is partly due to a lack of specificity in metabolomics databases. Though impressive in depth and breadth, the sheer magnitude of currently available databases is in part what makes them ineffective for many metabolomics studies. While still in pilot phases, our experience suggests that custom-built databases, developed using empirical data from specific sample types, can significantly improve confidence in IDs. While the concept of sample type specific databases (STSDBs) and spectral libraries is not entirely new, inclusion of unique descriptors such as detection frequency and quality scores, can be used to increase confidence in results. These features can be used alone to judge the quality of a database entry, or together to provide filtering capabilities. STSDBs rely on and build upon several available tools for compound ID and are therefore compatible with current compound ID strategies. Overall, STSDBs can potentially result in a new paradigm for translational metabolomics, whereby investigators confidently know the identity of compounds following a simple, single STSDB search.
format Online
Article
Text
id pubmed-7023092
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70230922020-03-12 A Perspective and Framework for Developing Sample Type Specific Databases for LC/MS-Based Clinical Metabolomics Reisdorph, Nichole A. Walmsley, Scott Reisdorph, Rick Metabolites Perspective Metabolomics has the potential to greatly impact biomedical research in areas such as biomarker discovery and understanding molecular mechanisms of disease. However, compound identification (ID) remains a major challenge in liquid chromatography mass spectrometry-based metabolomics. This is partly due to a lack of specificity in metabolomics databases. Though impressive in depth and breadth, the sheer magnitude of currently available databases is in part what makes them ineffective for many metabolomics studies. While still in pilot phases, our experience suggests that custom-built databases, developed using empirical data from specific sample types, can significantly improve confidence in IDs. While the concept of sample type specific databases (STSDBs) and spectral libraries is not entirely new, inclusion of unique descriptors such as detection frequency and quality scores, can be used to increase confidence in results. These features can be used alone to judge the quality of a database entry, or together to provide filtering capabilities. STSDBs rely on and build upon several available tools for compound ID and are therefore compatible with current compound ID strategies. Overall, STSDBs can potentially result in a new paradigm for translational metabolomics, whereby investigators confidently know the identity of compounds following a simple, single STSDB search. MDPI 2019-12-21 /pmc/articles/PMC7023092/ /pubmed/31877765 http://dx.doi.org/10.3390/metabo10010008 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Reisdorph, Nichole A.
Walmsley, Scott
Reisdorph, Rick
A Perspective and Framework for Developing Sample Type Specific Databases for LC/MS-Based Clinical Metabolomics
title A Perspective and Framework for Developing Sample Type Specific Databases for LC/MS-Based Clinical Metabolomics
title_full A Perspective and Framework for Developing Sample Type Specific Databases for LC/MS-Based Clinical Metabolomics
title_fullStr A Perspective and Framework for Developing Sample Type Specific Databases for LC/MS-Based Clinical Metabolomics
title_full_unstemmed A Perspective and Framework for Developing Sample Type Specific Databases for LC/MS-Based Clinical Metabolomics
title_short A Perspective and Framework for Developing Sample Type Specific Databases for LC/MS-Based Clinical Metabolomics
title_sort perspective and framework for developing sample type specific databases for lc/ms-based clinical metabolomics
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023092/
https://www.ncbi.nlm.nih.gov/pubmed/31877765
http://dx.doi.org/10.3390/metabo10010008
work_keys_str_mv AT reisdorphnicholea aperspectiveandframeworkfordevelopingsampletypespecificdatabasesforlcmsbasedclinicalmetabolomics
AT walmsleyscott aperspectiveandframeworkfordevelopingsampletypespecificdatabasesforlcmsbasedclinicalmetabolomics
AT reisdorphrick aperspectiveandframeworkfordevelopingsampletypespecificdatabasesforlcmsbasedclinicalmetabolomics
AT reisdorphnicholea perspectiveandframeworkfordevelopingsampletypespecificdatabasesforlcmsbasedclinicalmetabolomics
AT walmsleyscott perspectiveandframeworkfordevelopingsampletypespecificdatabasesforlcmsbasedclinicalmetabolomics
AT reisdorphrick perspectiveandframeworkfordevelopingsampletypespecificdatabasesforlcmsbasedclinicalmetabolomics